Federated Hermes’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.83M Sell
56,351
-76
-0.1% -$11.4K 0.01% 714
2026
Q1
$8.62M Sell
56,427
-962
-2% -$147K 0.01% 681
2025
Q4
$7.91M Buy
57,389
+5,967
+12% +$781K 0.01% 693
2025
Q3
$6.59M Sell
51,422
-48,181
-48% -$5.88M 0.01% 685
2025
Q2
$12.1M Sell
99,603
-1,473
-1% -$166K 0.02% 527
2025
Q1
$11.3M Buy
101,076
+12,821
+15% +$1.36M 0.02% 533
2024
Q4
$8.59M Sell
88,255
-6,233
-7% -$665K 0.02% 585
2024
Q3
$10.9M Sell
94,488
-3,448
-4% -$391K 0.02% 555
2024
Q2
$10.4M Sell
97,936
-12,266
-11% -$1.23M 0.02% 546
2024
Q1
$10.7M Sell
110,202
-9,853
-8% -$1.01M 0.02% 558
2023
Q4
$12.1M Sell
120,055
-3,696
-3% -$357K 0.03% 516
2023
Q3
$12.6M Sell
123,751
-2,935
-2% -$298K 0.03% 475
2023
Q2
$12.8M Sell
126,686
-16,220
-11% -$1.62M 0.03% 489
2023
Q1
$13.1M Buy
142,906
+6,387
+5% +$558K 0.03% 485
2022
Q4
$12.4M Sell
136,519
-23,358
-15% -$1.97M 0.03% 494
2022
Q3
$12.2M Buy
159,877
+16,398
+11% +$1.36M 0.04% 484
2022
Q2
$12.1M Sell
143,479
-18,521
-11% -$1.62M 0.03% 510
2022
Q1
$14.2M Buy
162,000
+64,879
+67% +$5.62M 0.03% 525
2021
Q4
$8.49M Sell
97,121
-20,445
-17% -$1.7M 0.02% 691
2021
Q3
$9.62M Buy
117,566
+8,369
+8% +$753K 0.02% 653
2021
Q2
$9.96M Buy
109,197
+18,736
+21% +$1.67M 0.02% 660
2021
Q1
$7.73M Sell
90,461
-1,592
-2% -$143K 0.02% 733
2020
Q4
$8.69M Sell
92,053
-1,091
-1% -$95.3K 0.02% 679
2020
Q3
$8.1M Sell
93,144
-2,824
-3% -$245K 0.02% 624
2020
Q2
$8.38M Sell
95,968
-27,206
-22% -$2.35M 0.02% 588
2020
Q1
$10.2M Buy
123,174
+63,830
+108% +$5.69M 0.03% 473
2019
Q4
$5.62M Sell
59,344
-2,128
-3% -$191K 0.01% 739
2019
Q3
$5.34M Sell
61,472
-1,465
-2% -$132K 0.01% 761
2019
Q2
$5.75M Sell
62,937
-54,941
-47% -$4.65M 0.01% 742
2019
Q1
$10.2M Sell
117,878
-53,415
-31% -$4.29M 0.03% 561
2018
Q4
$13.2M Sell
171,293
-3,043
-2% -$237K 0.04% 408
2018
Q3
$13.5M Buy
174,336
+36,837
+27% +$2.72M 0.03% 470
2018
Q2
$9.31M Sell
137,499
-5,480
-4% -$378K 0.03% 470
2018
Q1
$10.4M Sell
142,979
-131,195
-48% -$9.99M 0.03% 412
2017
Q4
$20.6M Buy
274,174
+1,618
+0.6% +$122K 0.06% 247
2017
Q3
$21M Sell
272,556
-34,109
-11% -$2.58M 0.06% 251
2017
Q2
$22.9M Sell
306,665
-2,348,781
-88% -$166M 0.07% 251
2017
Q1
$177M Buy
2,655,446
+526,324
+25% +$35.1M 0.5% 31
2016
Q4
$139M Buy
2,129,122
+2,066,057
+3,276% +$134M 0.42% 43
2016
Q3
$4.46M Buy
63,065
+5,408
+9% +$394K 0.01% 599
2016
Q2
$4.26M Buy
57,657
+4,231
+8% +$292K 0.01% 597
2016
Q1
$3.47M Buy
53,426
+2,363
+5% +$161K 0.01% 649
2015
Q4
$3.94M Sell
51,063
-1,597
-3% -$127K 0.01% 636
2015
Q3
$4.34M Sell
52,660
-27,971
-35% -$2.49M 0.01% 596
2015
Q2
$7.11M Buy
80,631
+4,926
+7% +$452K 0.02% 529
2015
Q1
$6.69M Buy
75,705
+27,189
+56% +$2.41M 0.02% 537
2014
Q4
$4.03M Buy
48,516
+12,349
+34% +$1.02M 0.01% 696
2014
Q3
$3.05M Buy
36,167
+17,972
+99% +$1.45M 0.01% 812
2014
Q2
$1.48M Buy
18,195
+9,016
+98% +$709K ﹤0.01% 1057
2014
Q1
$699K Buy
9,179
+769
+9% +$56K ﹤0.01% 1256
2013
Q4
$606K Buy
8,410
+2,667
+46% +$185K ﹤0.01% 1284
2013
Q3
$395K Sell
5,743
-217,177
-97% -$14.4M ﹤0.01% 1353
2013
Q2
$14.1M Buy
+222,920
New +$14.5M 0.06% 268

Other funds holding NVS

Federated Hermes's NVS Position: Q2 2026 in Review

Federated Hermes reduced its Novartis (NVS) stake by 0.13% in Q2 2026, selling an estimated $11.4K and leaving 56,351 shares worth $8.83M. The position accounts for 0.01% of the portfolio, ranked #714.

Federated Hermes first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $177M in Q1 2017. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Federated Hermes held 56,351 shares of Novartis worth $8.83M as of Q2 2026.
  • Federated Hermes sold 76 Novartis shares in Q2 2026, an estimated $11.4K.
  • Novartis made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #714 holding.
  • Federated Hermes first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Federated Hermes's Novartis position peaked at $177M in Q1 2017.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.